Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe

Contributed by: Business Wire

Logo

Tags

Biotechnology

Pharmaceutical

Health

Other Health

PYZCHIVA

More Like This

European Commission approves Celltrion’s SteQeyma® (CT-P43), a biosimilar to Stelara® (ustekinumab), for the treatment of multiple chronic inflammatory diseases

Samsung Bioepis to Commercialize BYOOVIZ® (ranibizumab) in Europe from January 2026

Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA

PR Newswire associated0

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®

FDA Accepts for Review BLA for DMB-3115 of Dong-A ST, a Proposed Biosimilar to Stelara® (Ustekinumab)

Accord Healthcare receives positive CHMP opinion for IMULDOSA®, a ustekinumab biosimilar to Stelara®

Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars

Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™)